Acute Myelomonocytic Leukemia
Symptoms, Doctors, Treatments, Advances & More

Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Naval Daver
Elite in Acute Myelomonocytic Leukemia
Dr. Naval Daver
Oncology
Elite in Acute Myelomonocytic Leukemia
Dr. Naval Daver
Oncology

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
713-794-4392
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is an Oncologist in Houston, Texas. Dr. Daver is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Acute Myelomonocytic Leukemia
Dr. Robert Fram
Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Robert Fram
Hematology

Office

128 Sidney St, 
Cambridge, MA 
617-995-4909
Languages Spoken:
English

Robert Fram is a Hematologist in Cambridge, Massachusetts. Dr. Fram is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Myelomonocytic Leukemia
Dr. Douglas Faller
Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Douglas Faller
Hematology

Office

720 Harrison Ave, 
Boston, MA 
617-638-6428
Languages Spoken:
English
See accepted insurances

Douglas Faller is a Hematologist in Boston, Massachusetts. Dr. Faller is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML).

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Phase: Phase 1

Summary: This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm
Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm
Enrollment Status: Recruiting
Publish Date: January 30, 2026
Intervention Type: Radiation, Drug, Procedure, Biological, Other
Study Phase: Phase 2

Summary: This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, called total body irradiation (TBI), and donor hematopoietic cell transplant (HCT) works in treating adults age 60 and older ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center